Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- 1 January 2009
- journal article
- case report
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 7 (1) , 24-27
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Targeted drugs for metastatic renal cell carcinomaThe Lancet, 2007
- Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2007
- Defining the Role of mTOR in CancerCancer Cell, 2007
- The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer TherapyClinical Cancer Research, 2007
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell CancerClinical Cancer Research, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- TemsirolimusDrugs of Today, 2007
- Targeting von Hippel-Lindau Pathway in Renal Cell CarcinomaClinical Cancer Research, 2006
- mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4EMolecular and Cellular Biology, 2004